Display options
Cite
Liu Y, Zhang X, Zhong JF. Current approaches and advance in mantle cell lymphoma treatment. Stem Cell Investig. 2015;2:18doi: 10.3978/j.issn.2306-9759.2015.09.02.
Liu, Y., Zhang, X., & Zhong, J. F. (2015). Current approaches and advance in mantle cell lymphoma treatment. Stem cell investigation, 218. https://doi.org/10.3978/j.issn.2306-9759.2015.09.02
Liu, Yao, et al. "Current approaches and advance in mantle cell lymphoma treatment." Stem cell investigation vol. 2 (2015): 18. doi: https://doi.org/10.3978/j.issn.2306-9759.2015.09.02
Liu Y, Zhang X, Zhong JF. Current approaches and advance in mantle cell lymphoma treatment. Stem Cell Investig. 2015 Sep 29;2:18. doi: 10.3978/j.issn.2306-9759.2015.09.02. eCollection 2015. PMID: 27358886; PMCID: PMC4923656.
Copy Download .nbib Format: NLM
Share it on

Stem Cell Investig. 2015 Sep 29;2:18. doi: 10.3978/j.issn.2306-9759.2015.09.02. eCollection 2015.

Current approaches and advance in mantle cell lymphoma treatment.

Stem cell investigation

Yao Liu, Xi Zhang, Jiang-Fan Zhong

Affiliations

  1. 1 Department of Hematology, Xinqiao Hospital, The Third Military Medical University, Chongqing 400037, China ; 2 Department of Pathology, University of Southern California, Keck School of Medicine, Los Angeles, CA 90033, USA.

PMID: 27358886 PMCID: PMC4923656 DOI: 10.3978/j.issn.2306-9759.2015.09.02

Abstract

Mantle cell lymphoma (MCL) is a set of heterogeneous non-Hodgkin lymphoma characterized by involvement of lymph nodes, spleen, bone marrow and blood. Under conventional treatment, survival time is 4 to 5 years with short remission period and there is still no standard treatment for MCL. In general, a close observation period called "watchful waiting" is used in elderly patients with low-risk slow clinical progress. And intensive chemotherapy including high-dose of cytarabine ± autologous hematopoietic stem cell transplantation (auto-HSCT) is recommended for younger and fit patients. Allogenic stem cell transplantation (allo-SCT) and drugs targeting the cell metabolic pathway, such as bortezomib (NF-κB inhibitor) and lenalidomide (anti-angiogenesis drug), are considerable treatments for relapsed/refractory patients. Clinical trials and less intensive chemotherapy such as R-CHOP (rituximab with cyclophosphamide, hydroxydaunomycin, oncovin and prednisone) and R-bendamustine should be considered for elderly MCL patients who are at intermediate/high risk. Recent clinical trials with ibrutinib (Bruton's Tyrosine Kinase inhibitor) and temsirolimus (mTOR inhibitor) have shown excellent efficacies in the treatment of MCL. This review will introduce the present status and major therapeutic progress in the treatment of MCL over recent years in order to provide a cutting edge to look into promising clinical progress of MCL.

Keywords: Mantle cell lymphoma (MCL); advance; standard chemotherapy

References

  1. Br J Haematol. 2013 Apr;161(1):43-56 - PubMed
  2. Cancer. 2008 May 15;112(10):2228-32 - PubMed
  3. J Clin Oncol. 2009 Dec 20;27(36):6101-8 - PubMed
  4. J Clin Oncol. 2009 Aug 10;27(23):3822-9 - PubMed
  5. Transplant Proc. 2004 Sep;36(7):1995-8 - PubMed
  6. J Clin Oncol. 2013 Apr 10;31(11):1442-9 - PubMed
  7. Blood. 2012 May 17;119(20):4597-607 - PubMed
  8. Ann Oncol. 2009 Mar;20(3):520-5 - PubMed
  9. J Clin Oncol. 2008 Jan 1;26(1):90-5 - PubMed
  10. J Clin Oncol. 2009 Nov 1;27(31):5213-8 - PubMed
  11. Biol Blood Marrow Transplant. 2013 Apr;19(4):625-31 - PubMed
  12. Blood. 2005 Apr 1;105(7):2677-84 - PubMed
  13. Blood. 2002 May 1;99(9):3158-62 - PubMed
  14. J Clin Oncol. 2002 Mar 1;20(5):1288-94 - PubMed
  15. Lancet Oncol. 2011 Apr;12(4):361-8 - PubMed
  16. J Clin Oncol. 2009 Nov 10;27(32):e189-90; author reply e191 - PubMed
  17. Ann Oncol. 2006 Sep;17 (9):1418-23 - PubMed
  18. Lancet Oncol. 2012 Jul;13(7):716-23 - PubMed
  19. J Clin Oncol. 2011 Feb 20;29(6):690-7 - PubMed
  20. Haematologica. 2007 Jan;92(1):42-9 - PubMed
  21. Biol Blood Marrow Transplant. 2010 Oct;16(10):1419-27 - PubMed
  22. Br J Haematol. 2008 Feb;140(4):385-93 - PubMed
  23. Crit Rev Oncol Hematol. 2012 Apr;82(1):78-101 - PubMed
  24. Br J Haematol. 2010 Jul;150(2):200-8 - PubMed
  25. J Clin Oncol. 2012 Sep 1;30(25):3119-26 - PubMed
  26. Blood. 2008 Oct 1;112(7):2687-93 - PubMed
  27. Haematologica. 2012 Jul;97(7):1085-91 - PubMed
  28. Leuk Lymphoma. 2012 Aug;53(8):1488-93 - PubMed
  29. Biol Blood Marrow Transplant. 2000;6(6):640-5 - PubMed
  30. Blood. 2009 Apr 30;113(18):4144-52 - PubMed

Publication Types